Interaction of clofibrate with warfarin. I. Effect of clofibrate on the disposition of the optical enantiomorphs of warfarin

Bjornsson, Thorir D.; Meffin, Peter J.; Blaschke, Terrence F.

doi:10.1007/bf01061730

Cited by 15 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study aimed to investigate, in four men receiving intravenous doses of radiolabelled phylloquinone, the potential interaction between clofibrate and warfarin on vitamin K disposition (Bjornsson et al, 1979). The authors indicate that the pool size of vitamin K in the body is 'small' but could not be calculated for these subjects.…”

Section: Storagementioning

confidence: 99%

See 1 more Smart Citation

Dietary reference values for vitamin K

Turck¹,

Bresson²,

Burlingame³

et al. 2017

EFS2

View full text Add to dashboard Cite

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) derives dietary reference values (DRVs) for vitamin K. In this Opinion, the Panel considers vitamin K to comprise both phylloquinone and menaquinones. The Panel considers that none of the biomarkers of vitamin K intake or status is suitable by itself to derive DRVs for vitamin K. Several health outcomes possibly associated with vitamin K intake were also considered but data could not be used to establish DRVs. The Panel considers that average requirements and population reference intakes for vitamin K cannot be derived for adults, infants and children, and therefore sets adequate intakes (AIs). The Panel considers that available evidence on occurrence, absorption, function and content in the body or organs of menaquinones is insufficient, and, therefore, sets AIs for phylloquinone only. Having assessed additional evidence available since 1993 in particular related to biomarkers, intake data and the factorial approach, which all are associated with considerable uncertainties, the Panel maintains the reference value proposed by the Scientific Committee for Food (SCF) in 1993. An AI of 1 lg phylloquinone/kg body weight per day is set for all age and sex population groups. Considering the respective reference body weights, AIs for phylloquinone are set at 70 lg/day for all adults including pregnant and lactating women, at 10 lg/day for infants aged 7-11 months, and between 12 lg/day for children aged 1-3 years and 65 lg/day for children aged 15-17 years.

show abstract

Section: Storagementioning

confidence: 99%

“…The Panel notes the uncertainties and methodological limitations of the studies by Jones et al (2008) and Bjornsson et al (1979), and considers that no conclusion can be drawn from these two studies to assess the total body pool of phylloquinone.…”

Section: Storagementioning

confidence: 99%

Dietary reference values for vitamin K

Turck¹,

Bresson²,

Burlingame³

et al. 2017

EFS2

View full text Add to dashboard Cite

show abstract

“…Clofibrate potentiates the action of warfarin by as much as 50% (Bjornsson et al 1977). Enhanced hypoglycaemic effects of sulfonylurea compounds used in the management of diabetes mellitus have also been reported under clofibrate therapy (Daubresse et al 1976).…”

mentioning

confidence: 94%

A Comparative Review of the Adverse Effects of Treatments for Hyperlipidaemia

1991

View full text Add to dashboard Cite

Various lipid-lowering drugs have been shown to reduce serum cholesterol and serum triglycerides effectively. In view of trials indicating that lipid-lowering drugs may reduce cardiac morbidity and mortality but not the overall mortality in the study group, increased attention must be focused on potential harmful side effects during treatment with these agents. The adverse effects of many of the principal drugs in this category are discussed. Gastrointestinal symptoms, usually self-limited and reversible, are the most common side effects. Potential harmful adverse effects include drug interactions (cholestyramine), myopathy and hepatic injury (HMG-CoA reductase inhibitors), and increased gallstone formation and ventricular arrhythmias (clofibrate). Not all lipid-lowering drugs have been studied adequately on a long term basis, so that medications given for an indefinite period must be reevaluated frequently. However, there are several agents that lower serum lipid levels effectively and that have been used for more than 20 years without serious side effects.

show abstract

“…Can increase the INR Acetaminophen [35][36][37] Unknown * Amiodarone 38,39 2C9 inhibition † Cimetidine 40,41 Enzyme inhibition Ciprofloxacin 42 Enzyme inhibition Clarithromycin 43,44 Enzyme inhibition Clofibrate 45,46 Enzyme inhibition Erythromycin 47,48 Enzyme inhibition Fluconazole 49,50 2C9 inhibition † Fluvastatin 51,52 2C9 inhibition Fluvoxamine 53 Enzyme inhibition Gemfibrozil 54 Enzyme inhibition Isoniazid 55 Enzyme inhibition Itraconazole 56 Enzyme inhibition Ketoconazole 57 Enzyme inhibition Lovastatin 58 Enzyme inhibition Metronidazole 59 2C9 inhibition † NSAIDs 76,77 Platelet inhibition ‡ Propafenone 60 Enzyme inhibition Simvastatin 61 Enzyme inhibition Tamoxifen 62,63 Enzyme inhibition Thyroid hormones 75 Increased vitamin K catabolism Tramadol 64,65 Enzyme inhibition Trimethoprim sulfamethoxazole 66 2C9 inhibition † Zafirlukast 67 2C9 inhibition…”

Section: Drug and Interaction Mechanism Of Interactionmentioning

confidence: 99%